Email Print this page Bookmark this page

For patients seeking improvement in comfort and satisfaction:2-4

Continuous lubrication, starting day 1.1-3
Provides ongoing ocular surface protection, long term.5

  • Results of a large multicenter registry study of over 400 patients showed significant reductions (P<0.05) in frequency and severity of dry eye symptoms after one month of therapy with LACRISERT®4
  • 53% of patients felt that LACRISERT improved the effectiveness of their existing therapy including artificial tears5
  • Patients reported significant improvements in discomfort, burning, dryness, grittiness, stinging, and symptom severity4

  • Mean Ocular Surface Disease Index (OSDI) total scores improved by 21.3% in 28 days (from 41.8± 22.38 to 32.9± 21.97)4*

Indications and Usage

LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT®.

The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

References: 1. LACRISERT [package insert] Madison, NJ: ATON Pharma, 2009 2. Hill J. Slow release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol. 1989;73:151-154. 3. Katz JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85:787-793. 4. Koffler BH, McDonald M, Nelinson D, Improved signs and symptoms and quality of life with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;3:170-176. 5. Wander A, Koffler B. Extending the duration of tear film production: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf. 2009;7(3e):154-162.

For full Prescribing Information, please click here.

LAC020-0411

sample request using Lacrisert video patient tip sheet
©2012 Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC          Bridgewater, NJ 08807